China vs India: The number of people with susceptibility test result for rifampicin
China
237,238
in 2021
India
673,008
in 2021
China rank
2nd
India rank
1st
The number of people with susceptibility test result for rifampicin over time
- China
- India
How they compare
India currently reports 673,008 against 237,238 in China, a difference of 435,770.
That makes India's figure about 2.8 times China's.
Across all 5 years both countries report, India has been ahead every year.
China ranks 2nd and India ranks 1st of 155 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | India | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 156,421 | 444,726 | 288,305 | India |
| 2020s | 242,912 | 615,232 | 372,320 | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or India?
- India, at 673,008 against 237,238 in China as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and India?
- 435,770, with India ahead.
- How many years of comparable data are there for China and India?
- 5 years are reported by both, from 2017 to 2021.
- How do China and India rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 2nd and India ranks 1st of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.